Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Vaccine | 1 |
Synthetic peptide | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein(SARS-CoV-2 S protein) | 1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CXCRs modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date27 Mar 2024 |
Sponsor / Collaborator |
Start Date06 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HexaPro (Vaxxas) ( SARS-CoV-2 S protein ) | COVID-19 More | Preclinical |
J8-DT | Streptococcal Infections More | Preclinical |
J8-DT+S2-DT ( CXCRs ) | Streptococcal Infections More | Pending |
MCC-8399 | Parasitic Diseases More | Pending |
Tamoxifen derivative(Griffith University) ( ER ) | Breast Cancer More | Pending |